Enlivex Therapeutics Stock Today
| ENLV Stock | USD 1.50 0.18 13.64% |
Performance0 of 100
| Odds Of DistressLess than 11
|
Enlivex Therapeutics is selling for under 1.50 as of the 24th of April 2024; that is 13.64 percent increase since the beginning of the trading day. The stock's lowest day price was 1.3. Enlivex Therapeutics has less than a 11 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Enlivex Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of March 2024 and ending today, the 24th of April 2024. Click here to learn more.
Business Domain Software & Services | IPO Date 12th of December 1995 | Category Healthcare | Classification Information Technology |
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel. Enlivex Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 18.6 M outstanding shares of which 236.38 K shares are currently shorted by private and institutional investors with about 2.38 trading days to cover. More on Enlivex Therapeutics
Follow Valuation Options Odds of Bankruptcy
Financial Report 21st of June 2024
Enlivex Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Enlivex Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Enlivex Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Shmuel Hess | ||||
| Business Concentration | Application Software, Software & Services, Information Technology, NASDAQ Composite, NASDAQ Health Care, Information Technology, Software, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation Analysts covering Enlivex Therapeutics report their recommendations after researching Enlivex Therapeutics' financial statements, talking to executives and customers, or listening in on Enlivex Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Enlivex Therapeutics. The Enlivex consensus assessment is calculated by taking the average forecast from all of the analysts covering Enlivex Therapeutics. | |||||
Enlivex Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Enlivex Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Enlivex Therapeutics' financial leverage. It provides some insight into what part of Enlivex Therapeutics' total assets is financed by creditors.
| |||||
Enlivex Therapeutics (ENLV) is traded on NASDAQ Exchange in USA. It is located in 14 Einstein Street, Ness Ziona, Israel, 7403618 and employs 19 people. Enlivex Therapeutics is listed under Application Software category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 24.55 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Enlivex Therapeutics's market, we take the total number of its shares issued and multiply it by Enlivex Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Enlivex Therapeutics conducts business under Software sector and is part of Information Technology industry. The entity has 18.6 M outstanding shares of which 236.38 K shares are currently shorted by private and institutional investors with about 2.38 trading days to cover.
Enlivex Therapeutics currently holds about 62.48 M in cash with (23.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Enlivex Therapeutics Probability Of Bankruptcy
Ownership AllocationEnlivex Therapeutics holds a total of 18.6 Million outstanding shares. Enlivex Therapeutics shows 11.8 percent of its outstanding shares held by insiders and 8.93 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Enlivex Ownership Details
Enlivex Stock Price Odds Analysis
Depending on a normal probability distribution, the odds of Enlivex Therapeutics jumping above the current price in 90 days from now is about 97.0%. The Enlivex Therapeutics probability density function shows the probability of Enlivex Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.082 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Enlivex Therapeutics will likely underperform. Additionally, enlivex Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Enlivex Therapeutics to move above the current price in 90 days from now is about 97.0 (This Enlivex Therapeutics probability density function shows the probability of Enlivex Stock to fall within a particular range of prices over 90 days) .
Enlivex Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Enlivex Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Enlivex Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Enlivex Therapeutics' value.| Instituion | Recorded On | Shares | |
| Advisor Group Holdings, Inc. | 2023-12-31 | 400 | |
| Bank Of America Corp | 2023-12-31 | 266 | |
| Jpmorgan Chase & Co | 2023-12-31 | 237 | |
| Advisory Services Network, Llc | 2023-12-31 | 43.0 | |
| Qube Research & Technologies | 2023-12-31 | 1.0 | |
| Goldman Sachs Group Inc | 2023-09-30 | 0.0 | |
| Srs Capital Advisors Inc | 2023-09-30 | 0.0 | |
| Susquehanna International Group Ltd | 2023-12-31 | 0.0 | |
| Simplex Trading, Llc | 2023-09-30 | 0.0 | |
| Renaissance Technologies Corp | 2023-12-31 | 62.1 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 44.5 K |
Enlivex Therapeutics Historical Income Statement
Enlivex Therapeutics Income Statement is one of the three primary financial statements used for reporting Enlivex's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Enlivex Therapeutics revenue and expense. Enlivex Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Enlivex Therapeutics' Research Development is fairly stable compared to the past year. Income Tax Expense is likely to climb to about 13.7 M in 2024, whereas Cost Of Revenue is likely to drop slightly above 793.2 K in 2024. View More FundamentalsEnlivex Stock Against Markets
Picking the right benchmark for Enlivex Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Enlivex Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Enlivex Therapeutics is critical whether you are bullish or bearish towards Enlivex Therapeutics at a given time. Please also check how Enlivex Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Enlivex Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Price Exposure Probability Now
Price Exposure ProbabilityAnalyze equity upside and downside potential for a given time horizon across multiple markets |
| All Next | Launch Module |
Enlivex Therapeutics Corporate Directors
Enlivex Therapeutics corporate directors refer to members of an Enlivex Therapeutics board of directors. The board of directors generally takes responsibility for the Enlivex Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Enlivex Therapeutics' board members must vote for the resolution. The Enlivex Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Abraham Havron | Director | Profile | |
| Sangwoo Lee | Director | Profile | |
| Baruch Halpert | Director | Profile | |
| Michel Habib | Director | Profile |
How to buy Enlivex Stock?
Before investing in Enlivex Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Enlivex Therapeutics. To buy Enlivex Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Enlivex Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Enlivex Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Enlivex Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Enlivex Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Enlivex Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.
Already Invested in Enlivex Therapeutics?
The danger of trading Enlivex Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Enlivex Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Enlivex Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Enlivex Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Enlivex Therapeutics is a strong investment it is important to analyze Enlivex Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Enlivex Therapeutics' future performance. For an informed investment choice regarding Enlivex Stock, refer to the following important reports: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Enlivex Stock analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Stocks Directory Find actively traded stocks across global markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities |
Is Enlivex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enlivex Therapeutics. If investors know Enlivex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enlivex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.47) | Return On Assets (0.30) | Return On Equity (0.67) |
The market value of Enlivex Therapeutics is measured differently than its book value, which is the value of Enlivex that is recorded on the company's balance sheet. Investors also form their own opinion of Enlivex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enlivex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enlivex Therapeutics' market value can be influenced by many factors that don't directly affect Enlivex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enlivex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enlivex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enlivex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.